氨基末端脑钠肽前体在无创通气治疗慢性阻塞性肺疾病合并肺心病疗效评估中的价值

目的:探讨氨基末端脑钠肽前体(NT-ProBNP)对无创通气治疗慢性阻塞性肺病(COPD)伴肺心病疗效评估的价值及其意义。方法:将97例COPD急性加重期合并肺心病患者随机分为常规治疗组(47例)和无创通气组(常规药物治疗加上无创通气治疗)(50例),动态观察患者的血气分析指标及血浆NT-ProBNP浓度。结果:治疗后两组患者血气分析指标明显改善(P<0.05),两组患者治疗后NT-ProBNP水平均呈下降趋势(P<0.05),但无创通气组下降更明显(P<0.05)。结论:无创通气治疗COPD并肺心病患者的NT-ProBNP下降更显著,NT-ProBNP可用于无创通气治疗COPD并肺心病的疗效评估。

The value of NT-ProBNP in evaluating the clinical efficacy of noninvasive ventilation on patients with chronic obstructive pulmonary disease and cor pulmonale

Objective:To investigate the value of N-terminal pro-brain natriuretic peptide(NT-ProBNP) in evaluating the clinical efficacy of noninvasive ventilation on patients with chronic obstructive pulmonary disease(C OPD) and cor pulmonale.Methods:Nighty-seven patients with acute exacerbation o f COPD patients with pulmonary heart disease,were randomly divided into two gro ups:routinal treatment group(47 cases);noninvasive ventilation group(routina l treatment plus non-invasive ventilation)(50 cases),and then detected blood gas analysis and the concentration of plasma NT-ProBNP.Results:After the treat ment,blood gas analysis index of patients′ in two groups improved significantl y(P<0.05),NT-ProBNP levels after treatment in the two groups were decrea sed(P<0.05),but the noninvasive ventilation group decreased more signific antly(P<0.05).Conclusion:NT-ProBNP were more significantly decreased aft er routinal treatment plus non-invasive ventilation,NT-Pro-BNP can be used t o evaluate the clinical efficacy of noninvasive ventilation in treatment of COPD and pulmonary heart disease.